151 related articles for article (PubMed ID: 22665530)
1. Characterization of potential CD138 negative myeloma "stem cells".
Christensen JH; Jensen PV; Kristensen IB; Abildgaard N; Lodahl M; Rasmussen T
Haematologica; 2012 Jun; 97(6):e18-20. PubMed ID: 22665530
[No Abstract] [Full Text] [Related]
2. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
4. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
6. Measurable disease evaluation in patients with myeloma.
Roshal M
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients.
Yousef S; Marvin J; Steinbach M; Langemo A; Kovacsovics T; Binder M; Kröger N; Luetkens T; Atanackovic D
Blood Cancer J; 2015 Mar; 5(3):e285. PubMed ID: 25747678
[No Abstract] [Full Text] [Related]
8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
9. Sample processing and methodological pitfalls in multiple myeloma research.
Potácová A; Stossová J; Buresová I; Kovárová L; Almási M; Penka M; Hájek R
Klin Onkol; 2011; 24 Suppl():S18-23. PubMed ID: 21923059
[TBL] [Abstract][Full Text] [Related]
10. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
11. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.
Reid S; Yang S; Brown R; Kabani K; Aklilu E; Ho PJ; Woodland N; Joshua D
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e190-6. PubMed ID: 20201998
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
13. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
14. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
15. Robust isolation of malignant plasma cells in multiple myeloma.
Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
[TBL] [Abstract][Full Text] [Related]
16. Seemingly insignificant, but crucial morphological leads in the diagnosis of non-secretory multiple myeloma in an adolescent.
Mishra J; Chopra A; Gogia A; Kumar R
Indian J Pathol Microbiol; 2012; 55(1):130-2. PubMed ID: 22499328
[No Abstract] [Full Text] [Related]
17. Diagnosis of rare entity CD138 negative plasma cell multiple myeloma: the synergy between laboratory and clinician makes the difference.
Assandri R; Inzoli A; Manini A; Fasoli G; Martinelli P; Grassini A
Recenti Prog Med; 2024 May; 115(5):238-242. PubMed ID: 38708535
[TBL] [Abstract][Full Text] [Related]
18. Novel type of clonally involved cytoplasmic immunoglobulin-negative cells in multiple myeloma: flow cytometric study.
Shimazaki C; Gotoh H; Oku N; Ashihara E; Inaba T; Murakami S; Ura Y; Nakagawa M; Fujita N
Acta Haematol; 1992; 88(2-3):86-91. PubMed ID: 1466204
[TBL] [Abstract][Full Text] [Related]
19. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
[TBL] [Abstract][Full Text] [Related]
20. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
